Abcam, ab286591, Human FLT4 knockout HCT116 cell line

Size: 1000000Cells / vial / 2 x 1000000Cells / vial
FLT4 KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control available. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:HCT116,
Species or organism:Human,
Tissue:Colon,
Form:LiquidSee storage information,
Knockout validation:Next Generation Sequencing,
Disease:Carcinoma

Product details:
Although we aim to provide customers with a homozygous clone, feasibility will be dependent on the biology of the protein. Should only heterozygous edits be achieved, you will be notified of the outcome and be asked to confirm whether the cell line is acceptable. All clones will be accompanied with DNA sequencing data, and the mutation description.
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-FLT4, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
VEGF Receptor 3 also known as FLT-4 is a protein essential for lymphatic development and is expressed mainly in lymphatic endothelial cells. This receptor has a molecular mass of approximately 195 kDa. VEGF Receptor 3 belongs to the tyrosine kinase family and binds with high affinity to its ligands VEGF-C and VEGF-D. These interactions lead to the activation of intracellular signaling cascades that promote cell proliferation migration and survival.
Biological function summary
The VEGF Receptor 3 acts as an important regulator of lymphangiogenesis which is the growth of new lymphatic vessels from pre-existing ones. It is not typically part of larger protein complexes but it works closely with its ligands to facilitate the processes associated with lymph vessel formation and function. Proper activity of VEGF Receptor 3 is necessary for maintaining normal lymphatic vessel remodeling and function during development and in some adult tissues.
Pathways
The receptor is involved in the VEGF signaling pathway which plays an important role in vascular and lymphatic development. This pathway intersects with others like the PI3K/AKT pathway a critical mediator of cell growth and survival. VEGF Receptor 3 interacts with related receptors such as VEGF Receptor 2 in these pathways to regulate complex and essential physiological processes.
VEGF Receptor 3 has been linked to lymphedema which is swelling due to lymphatic system dysfunction and certain cancers where excessive angiogenesis occurs. Mutations or dysregulations in the receptor's signaling can lead to these conditions. In cancer for instance VEGF Receptor 3 along with its associated protein VEGF-C can promote tumor lymphangiogenesis facilitating metastasis. Antagonists like anti-VEGF therapies target these receptors to inhibit tumor progression and manage these disorders.